{"id":"W2473317929","doi":"10.1200/jco.2015.33.3_suppl.512","title":"RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Medicine; FOLFIRI; Ramucirumab; Internal medicine; Clinical endpoint; Hazard ratio; Irinotecan; Progression-free survival; Phases of clinical research; KRAS; Oncology; Log-rank test; Gastroenterology; Colorectal cancer; Randomized controlled trial; Clinical trial; Proportional hazards model; Cancer; Chemotherapy; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002593082,0.0004714043,0.004109829,0.0003473114,0.0001389735,0.00003430543,0.0001409981,0.0002110717,0.00002906056],"category_scores_gemma":[0.001731779,0.0002417653,0.0002532631,0.0003664379,0.0004216885,0.0003227411,0.0001320563,0.0007295592,5.007242e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000528476,"about_ca_system_score_gemma":0.001369155,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002425947,"about_ca_topic_score_gemma":0.002756661,"domain_scores_codex":[0.9944976,0.0008052456,0.002921004,0.0005093606,0.0008536356,0.0004131285],"domain_scores_gemma":[0.9933339,0.002372556,0.002672639,0.0002129017,0.0009589687,0.0004490011],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8525015,0.01654315,0.09581168,0.0001011472,0.003181319,0.002217413,0.005526056,0.0000339267,0.000007581496,0.000001763986,0.00001285968,0.02406158],"study_design_scores_gemma":[0.7641538,0.1920314,0.03766245,0.0003594237,0.001982928,0.000299215,0.002588848,0.0005701176,0.0001032053,0.000009986718,0.00002862329,0.0002100713],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9918802,0.001408944,0.00002754409,0.0006363743,0.0002752621,0.005699764,0.000008510855,0.00001496199,0.00004837982],"genre_scores_gemma":[0.9977482,0.0004331628,0.00120318,0.00007963066,0.0001130623,0.000312324,0.00001086647,0.00004502822,0.00005453618],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1754882,"threshold_uncertainty_score":0.9858902,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1348567628289724,"score_gpt":0.4327987403504687,"score_spread":0.2979419775214963,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}